ArticleNeoplasia (New York, N.Y.)2024
Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations.
Kai Xiong et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.